Paroxetine Dosing Guidelines
Start paroxetine at 20 mg once daily in the morning for most adults with depression or anxiety disorders, but reduce the initial dose to 10 mg daily in elderly patients (≥60 years), those with severe hepatic impairment, or severe renal impairment (creatinine clearance <30 mL/min). 1
Standard Adult Dosing
For major depressive disorder, panic disorder, social anxiety disorder, PTSD, and generalized anxiety disorder, the established effective dose is 20 mg/day taken as a single morning dose with or without food 1.
- The therapeutic range is 20-50 mg/day for most indications
- For OCD specifically, higher doses (40-60 mg/day) demonstrate superior efficacy 1
- Dose increases should occur in 10 mg increments at minimum 1-week intervals
- Maximum dose: 50 mg/day (general); 60 mg/day (OCD only)
- Do not exceed 40 mg/day in elderly or impaired patients 1
The FDA label establishes these doses based on controlled trials showing clear dose-response relationships, particularly for OCD where 40-60 mg significantly outperformed 20 mg 1.
Special Population Adjustments
Elderly Patients (≥60 years)
Start at 10 mg/day and titrate cautiously 1. Elderly patients demonstrate 70-80% higher minimum plasma concentrations compared to younger adults due to reduced clearance 1. Clinical trial data confirm that controlled-release paroxetine 12.5-25 mg daily is effective and well-tolerated in patients ≥60 years, though the 25 mg dose shows larger effect sizes 2.
Hepatic Impairment
Start at 10 mg/day in patients with any degree of hepatic impairment 1. Cirrhotic patients show approximately 2-fold increases in AUC and Cmax, with elimination half-life prolonged to 83 hours versus 36 hours in controls 3. Dose-corrected steady-state concentrations are more than doubled (89 vs 43 h·ng/mL per mg) 3. The saturable CYP2D6 metabolism pathway becomes further compromised in liver disease 1.
Severe Renal Impairment
Start at 10 mg/day when creatinine clearance is <30 mL/min 1. Plasma concentrations are approximately 4-fold higher in severe renal impairment; moderate impairment (CrCl 30-60 mL/min) produces 2-fold increases 1.
Adolescents
The FDA has not approved paroxetine for pediatric depression 4. Black box warnings exist for treatment-emergent suicidality in adolescents and young adults 4. If used off-label, apply the same cautious low-dose initiation as in elderly patients.
Pharmacokinetic Considerations
Paroxetine exhibits nonlinear, saturable kinetics due to CYP2D6 pathway saturation at clinical doses 1. This means:
- Steady-state is reached in 7-14 days
- Dose doubling (20→40 mg) produces only 2-3 fold concentration increases, not proportional doubling 1
- Elimination half-life averages 21 hours but shows 32% coefficient of variation 1
- CYP2D6 poor metabolizers will have substantially higher exposures 4
Critical pitfall: The saturable metabolism means adverse effects may emerge disproportionately with dose escalation. Nausea occurs in nearly all cirrhotic patients at standard doses 3.
Discontinuation Strategy
Never stop abruptly. Taper gradually by reducing dose incrementally over weeks 1. For high-dose regimens (≥40 mg), an even more gradual taper is essential given the elevated steady-state concentrations 5. If intolerable withdrawal symptoms emerge, resume the previous dose and taper more slowly 1.
Therapeutic Drug Monitoring
Emerging evidence suggests therapeutic serum concentration ranges of 15-125 ng/mL for males and 30-210 ng/mL for females 5, though routine TDM is not standard practice. Consider monitoring in poor responders, suspected non-adherence, or when drug interactions are present.
Drug Interactions
Allow 14 days washout when switching to/from MAOIs 1. Paroxetine potently inhibits CYP2D6, affecting metabolism of many co-administered drugs 1. Avoid concurrent NSAIDs, aspirin, or anticoagulants when possible due to increased bleeding risk 1.